THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Franck Gallardo, Founder & CEONeoVirTech brings ANCHORTM to the table— a technology to investigate live cell dynamics of viruses by visualizing the way they attack the living cells. Pharmaceutical companies resort to several methods such as target-based approach, reporter cell line, and High-throughput Screening (HTS) platforms, for the discovery and research of antiviral medications. But these approaches are often inefficient. For instance, the reporter cell line method is an indirect measurement; the approach of accumulating virus’ nucleic acid by quantitative PCR will represent only an average measurement of all the sample event that occurs in a specific condition. Essentially, these methods fail to provide qualitative data for quantitative experiments. A viable solution for this predicament is a cost-effective screening technique that can quantify the replication process of viruses in real time.
“ANCHORTM technology is capable of studying cell dynamics of virus infections, their replication, and propagation to produce high-resolution images of the same” mentions Franck Gallardo, CEO, NeoVirTech. The solution allows researchers to perform phenotypic screening by considering the infection as a single test material.
ANCHORTM can also be used to study the effects of drugs on viruses, cells, and the interaction of host pathogens with the cells either as inhibitors or as activators during the screening alone. The technology also gives a direct read-out of the effects of potential inhibitors on virus infections without the need for any fixation, extraction, and reagents. In effect, this speeds up the research processes and saves time and money. For complex viruses whose readouts are difficult to obtain, ANCHORTM offers direct visualization of the viral copy number. Moreover, NeoVirTech’s state of the art image analysis facility augments the process of antiviral discovery.
ANCHOR technology is capable of studying cell dynamics of virus infections, their replication, and propagation to produce high-resolution images of the same
For conducting experiments, NeoVirTech uses their internal collection of viruses, or they generate custom auto-fluorescent viruses in accordance with their customers’ requirements. The viruses can then be studied on their high-resolution screening platform, on FDA/EMEA approved library of compounds or on the customer’s compounds of interest. Researchers can even implement NeoVirTech’s auto-fluorescent technology in their own laboratories. “We provide our expertise in antiviral screening besides focusing on the pharmaceutical market that include developing drugs for both human and animal health and bio-defense programs,” says Gallardo. The company is also serving growing markets where viruses are used as a component for manufacturing healthcare products such as devices for gene therapy, prophylactic agents (vaccine), and anti-cancer agents (oncolytics).
Besides focusing more on research on life-threatening infections and epidemics affecting both human and animal life, NeoVirTech is also undertaking experiments on discovering antiviral treatments for conditions for which cure does not exist to date. Divulging NeoVirtech’s future endeavors, Gallardo mentions that the firm is in the process of developing anti-HIV screening by being able to directly discover drugs that impact on the infection, retrotranscription, integration, and persistence of HIV genome inside living cells.
Company
NeoVirTech
Management
Franck Gallardo, Founder & CEO
Description
The company provides ANCHOR, an
autofluorescence technology for rapid and
efficient viral vector imaging and antiviral
discovery
“The structural growth of the API division is a key component in NerPharMa's strategic plan. In order to reach the highest potential of our facilities, we see the partnership with ICROM as an essential step to accelerate the process to offer our customers concrete and qualitatively high-tech solutions in a very short time”, said Angelo Colombo CEO of NerPharMa.”
“We are extremely excited about this partnership with a leading enterprise that has been operating in the sector with proven successes for many years” said Pierfrancesco Morosini, CEO of ICROM, “I am absolutely convinced that the synergy of the capabilities and potentials of the two companies will bring us mutually beneficial outcome, in this fierce global competition context.”